Harrow Health Inc is primarily active in the healthcare industry.

The main competitors of Harrow Health Inc in the market include pharmaceutical companies such as Johnson & Johnson, Pfizer Inc, and Novartis AG.

Harrow Health Inc, formerly known as Imprimis Pharmaceuticals, is a pharmaceutical company specializing in the development and commercialization of innovative therapeutic products. Founded in 2006, the company initially focused on providing compounded medications to patients and physicians. Over the years, Harrow Health Inc expanded its portfolio, acquiring multiple ophthalmology-focused businesses and broadening its reach within the eye care industry. Today, the company's offerings include both FDA-approved and compounded medications, along with proprietary formulations and drug delivery technologies. Harrow Health Inc continues to demonstrate its commitment to improving patient access to high-quality, affordable healthcare solutions within the pharmaceutical sector.

Harrow Health Inc has accomplished several significant milestones in its history. Firstly, the company successfully expanded its pharmaceutical portfolio by acquiring Imprimis Pharmaceuticals, which greatly enhanced its product offering and market presence. Additionally, Harrow Health Inc implemented strategic partnerships and collaborations to further its growth and innovation. The company also achieved financial milestones by consistently delivering positive financial results and increasing its revenue over time. Furthermore, Harrow Health Inc demonstrated its commitment to advancing patient care by successfully launching innovative drugs and expanding its prescription services. These achievements highlight Harrow Health Inc's continuous progress, strong market position, and dedication to improving healthcare outcomes.

Harrow Health Inc is primarily present in the United States.

Harrow Health Inc represents values of innovation, patient care, and ethical practices. The company strives to develop and deliver high-quality medications and healthcare solutions that improve patient outcomes and advance medical treatments. Harrow Health Inc is committed to providing accessible and affordable pharmaceuticals while maintaining strict regulatory compliance. With a focus on research and development, the company aims to address unmet medical needs and introduce pioneering therapies to enhance overall patient well-being. Harrow Health Inc's corporate philosophy revolves around integrity, transparency, and putting patients first, driving its mission to make a significant impact in the healthcare industry.

Analysts currently set an average price target of 72,13 USD for the Harrow stock (median: 70,38 USD), implying +70,9 % versus the latest price. The consensus is based on 14 analyst ratings.

Harrow Prezzi Obiettivo Analisti 2026

14 analysts currently rate the Harrow stock: 13 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Harrow to generate revenue of 348,47 Mio. USD and earnings per share of 0,45 USD.

Harrow Prezzi Obiettivo Analisti 2026

Converted at the current exchange rate, the Harrow share trades at 33,06 EUR (38,52 USD).

The Harrow share (HROW) is listed on 1 stock exchanges, including: NASDAQ (HROW).

Harrow Health Inc is a company that specializes in the development, marketing, and sale of high-quality pharmaceuticals and medical devices. Its business model is focused on the field of ophthalmology medicine, which is a specialized niche with a high demand for innovative products and services. The company offers its products and services in various areas, including the development of eye drops and steroids. It works closely with doctors and other medical professionals to understand the needs of patients in this area and develop innovative solutions that deliver better results for patients. Another important area in which the company operates is the production of eye implants and lenses suitable for patients with a variety of eye conditions. The different types of lenses range from intraocular lenses for vision correction to multifocal lenses for older patients. Harrow Health is also active in the production of medical devices and offers a wide range of products that can be used for eye treatment. The company manufactures medical instruments for use in surgeries, diagnostic instruments for early detection of eye diseases, and even devices for data processing and analysis. One of Harrow Health's standout products is the Buccolam medication, which was developed for the treatment of epilepsy in children and adults. Buccolam is a fast-acting seizure medication offered in a rapidly dispersible formulation and is an incredibly effective treatment for seizures. Overall, the company relies on a diversified business model to ensure that it can respond to market needs while also building a stable and sustainable business. By focusing on multiple areas of ophthalmology medicine and offering a wide range of products and services, Harrow Health ensures that it can serve a variety of customers and operate very successfully in the market. In summary, Harrow Health is a strong company that specializes in pharmaceutical and medical technology for eye care. With its wide range of products such as eye drops, implants, and medical instruments, the company ensures that it can respond to the needs of patients in this field and remain relevant to ophthalmology medicine.

Il attesa fatturato di Harrow ammonta a 348,47 Mio. USD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.

Il attesa profitto di Harrow ammonta a 16,42 Mio. USD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.

Il rapporto prezzo/utili (P/E) di Harrow è attualmente 86,23. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Harrow.

Il rapporto prezzo/fatturato (P/S) di Harrow è attualmente 4,06. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Harrow.

Il Quality Score AlleAktien per Harrow è 5/10.

L'ISIN di Harrow è US4158581094. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.

Il WKN di Harrow è A2PBJD. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.

Il ticker di Harrow è HROW. Con questo simbolo di borsa vengono negoziate le azioni Harrow in borsa.

Harrow ha pagato dividendi ogni anno negli ultimi 0 anni.

Harrow è assegnato al settore 'Sanità'.

I dividendi di Harrow sono distribuiti in USD.